Docetaxel-Based Triplet New Standard in Gastric Cancer
Perioperative chemotherapy with a docetaxel-based triplet should be considered the new standard of care for resectable gastric or GEJ adenocarcinoma.
Lenvatinib for Unresectable Liver Cancer Noninferior to Sorafenib
Lenvatinib demonstrated noninferiority to sorafenib with regard to overall survival in patients with previously untreated, unresectable hepatocellular carcinoma.
PEGPH20 Could Improve Metastatic Pancreatic Cancer Outcomes
Adding PEGPH20 to nab-paclitaxel and gemcitabine improved progression-free survival in patients with untreated, metastatic pancreatic ductal adenocarcinoma.
New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer
In this article we will discuss the definitions of resectability, describe the current diagnostic tests for pancreatic cancer, and review strategies for maximizing treatment outcomes in patients with resectable pancreatic cancer.
Healthy Lifestyle Extended Survival After Colon Cancer Diagnosis
Patients with stage III colon cancer who maintained a healthy lifestyle had a reduced risk for death and a trend for a lower chance of recurrence.
Single Surveillance Visit Reduced CRC Incidence in Adenoma Patients
Attending at least one surveillance visit with colonoscopy benefited most patients diagnosed with intermediate-risk adenomas, according to the results of a retrospective study.
Adjuvant Oral Chemo in Biliary Tract Cancer Extended Survival
The addition of adjuvant oral chemotherapy with capecitabine extended the overall survival of patients with biliary cancers by a median of 15 months, according to the results of the BILCAP study.
By clicking Accept, you agree to become a member of the UBM Medica Community.